Results 41 to 50 of about 869,771 (326)
Nihon rinsho. Japanese journal of clinical medicine, 2016 Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec-
Arias Santiago, Salvador Antonio +1 more
openaire +5 more sources
The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions [PDF]
, 2011 C-Kit (CD117), the receptor for the stem cell factor, a growth factor for melanocyte migra- tion and proliferation, has shown differential immunostaining in various benign and malig- nant melanocytic lesions. The purpose of this study is to compare c-Kit
Atzori L +9 more
core +1 more source
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade [PDF]
, 2019 Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N6-methyladenosine (m6A) mRNA demethylation by fat mass and obesity-associated protein (FTO) increases melanoma growth and decreases response to anti-PD-1 blockade ...
Aplin, Andrew E. +10 more
core +1 more source
Local treatment failure after globe-conserving therapy for choroidal melanoma. [PDF]
, 2013 Local treatment failure after globe-conserving therapy for choroidal melanoma is a surgical complication with significant morbidity to the vision and eye. Few reports in the literature have addressed this complication exclusively.
Chang, Melinda Y, McCannel, Tara A
core +1 more source
Single‐cell insights into the role of T cells in B‐cell malignancies
FEBS Letters, EarlyView.Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley +1 more source
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
Frontiers in Immunology, 2021 Acral and mucosal melanomas are extremely rare in Caucasians; however, they are the predominant melanoma subtypes in Asians and other non-Caucasian populations.
Lili Mao +4 more
doaj +1 more source
Melanocortin 1 receptor targeted imaging of melanoma with gold nanocages and positron emission tomography [PDF]
, 2018 Purpose: Melanoma is a lethal skin cancer with unmet clinical needs for targeted imaging and therapy. Nanoscale materials conjugated with targeting components have shown great potential to improve tumor delivery efficiency while minimizing undesirable ...
Black, Kvar +8 more
core +2 more sources
FEBS Letters, EarlyView.Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu +17 more
wiley +1 more source
Nature CommunicationsThe biological underpinnings of therapeutic resistance to immune checkpoint inhibitors (ICI) in adolescent and young adult (AYA) melanoma patients are incompletely understood.
Xinyu Bai +14 more
doaj +1 more source
Trials, 2020 Background The Melanoma Genomics Managing Your Risk Study is a randomised controlled trial that aims to evaluate the efficacy of providing information on personal genomic risk of melanoma in reducing ultraviolet radiation (UV) exposure, stratified by ...
Serigne N. Lo +4 more
doaj +1 more source